Drug Trial Radar · NCT07472491
A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients
Last checked: Nov 19, 2026Latest source record: Jun 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
640
Planned (sponsor's estimate)
Start
Apr 1, 2026
Primary completion
Nov 30, 2027
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- GE HealthcareIndustry
- Sponsor type
- Industry
- First posted
- Mar 16, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an operationally combined Phase 2/3 study, which will be conducted and evaluated in 2 distinct parts: * Phase 2: Prospective, adaptive, multicenter, non-randomized, single-blind, dose-finding, including participants with known or highly suspected lesions of the CNS. The aim of the Phase 2 part is to identify an optimized dose of mangaciclanol for the Phase 3 part of the study. * Phase 3: Prospective, multicenter, randomized, controlled, single-blind, cross-over, including participants with known or highly suspected lesions of the CNS or body. The aim of the Phase 3 part is to further evaluate the efficacy and safety of mangaciclanol-enhanced MRI for the detection and characterization of lesions of the CNS or body. The investigational medicinal products (IMPs) used during the trial are mangaciclanol and gadobutrol (comparator IMP). Primary and key secondary efficacy analyses will be based on independent central blinded image evaluation (BIE), and Phase 2 data will be analyzed prior to commencement of Phase 3.
Conditions
- Known or Highly Suspected Central Nervous System (CNS) Lesion
- Known or Highly Suspected Body (Excluding CNS) Lesion
Interventions
Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mLDrug
Single intravenous (IV) administration of Mangaciclanol (GEH200486 Injection, 0.5 mmol/mL) followed by a 20mL saline flush
MRI ScanDiagnostic test
MRI Scan starting prior to IMP administration and continuing for up to 60 minutes post IMP administration
GadobutrolDrug
Single intravenous (IV) administration of Gadobutrol (0.1 mmol/kg) followed by a 20mL saline flush
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 2 Primary Endpoint - Overall diagnostic preferenceTime frame: 4-47 days
- Phase 3 Primary Endpoint - Lesion visualization criteriaTime frame: 4-74 days
Locations
7 sites in 4 countries. Site status is shown where the registry gives one.
Mayo Clinic
Rochester, Minnesota · Recruiting
Renovatio Clinical
The Woodlands, Texas · Recruiting
LTD Israel-Georgian Medical Research Clinic Healthycore
Tbilisi, Georgia · Recruiting
LTD New Hospitals
Tbilisi, Georgia · Recruiting
LLC Todua Clinic
Tbilisi, Georgia · Recruiting
Arensia Exploratory Medicine - Moldova - IMSP Spitalul Clinic Republican Timofei Mosneaga
Chisinau, Moldova · Recruiting
Seoul National University Hospital
Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.